Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors

Apr 16, 2020 | Top Stories

By 99percent

News_Update_-_99percent

Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors
Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors 3For years, Gilead Sciences’ (NASDAQ:GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company’s revenues have experienced an enormous decline from 2015 onwards, falling over $10 billion in the past four years as patients cured of …
News story posted on 2020-04-16T17:43:00.0000000Z

Explore More Stories of Activism and Change

0 Comments